Tarsus Pharma up on positive trial data for Lyme disease prevention drug

Tarsus Pharmaceuticals

22/02/2024 15:23

(Updates)
    ** Tarsus Pharmaceuticals'  TARS.O  shares up 3.9% at $31.30
    ** Company reports positive data from mid-stage trial of
investigational oral therapeutic for prevention of Lyme disease
    ** Lyme disease is a tick-borne disease that results in
rashes, fever and fatigue 
    ** The trial tested the ability of therapeutic TP-05 to kill
ticks attached to subjects with a single treatment compared to
placebo
    ** Both the high and low doses demonstrated a statistically
significant benefit in killing ticks compared to placebo,
company says
    ** TARS management will look to outlicense or partner the
asset as it does not fit within company's core focus of eye care
- brokerage William Blair
    ** "The deal could be a source of non-dilutive capital to
support the ongoing launch of Xdemvy, its anti-parasitic eye
drop" - brokerage
    ** Tarsus shares rose 38% in 2023

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))